Neglected Disease Research and Development: The Ebola Effect
The eighth G-FINDER survey reports on 2014 global investment into research and development (R&D) of new products for neglected diseases, and identifies trends and patterns across the eight years of global G-FINDER data. In all, 198 organisations completed the survey in 2014, which covered:
- 35 neglected diseases
- 142 product areas for these diseases, including drugs, vaccines, diagnostics, microbicides and vector control products
- Platform technologies (adjuvants, delivery technologies, diagnostic platforms)
- All types of product-related R&D, including basic research, discovery and preclinical, clinical development, Phase IV and pharmacovigilance studies, and baseline epidemiological studies. In 2014, following a review by our Advisory Committee, the survey expanded to include Ebola and additional hepatitis C genotypes (5 and 6).
Visit the Policy Cures website to learn more about the G-Finder reports.